Subscribe to Biological Therapies in Psychiatry -  Choose your plan >
IN THIS MONTH'S ISSUE:
February 2017

Mood Stabilizers during Pregnancy: Clinical Updates
Based on current data of in utero exposure to mood stabilizers, valproic acid (Depakene, Depakote, and others) and carbamazepine (Tegretol and others) present the greatest risk for adverse long-term neurobehavioral outcomes, whereas lithium and lamotrigine (Lamictal and others) so far appear to be safe. Antipsychotics have not been adequately studied.

Ongoing Treatment for BDD
Of patients with body dysmorphic disorder who respond to initial treatment with selective serotonin reuptake inhibitors (SSRIs), those who are continued on SSRI treatment for 6 months show greater improvement and longer time to relapse than those switched to placebo.

In Brief
FDA Removes Black Box Warning for Smoking Cessation Drugs Varenicline and Bupropion; Low Levels of Brain-Derived Neurotrophic Factor Decrease Depressed Patients Response to Chemotherapy

Antihypertensives and the Risk of Mood Disorders
In a Scottish retrospective study, patients who took angiotensin antagonist antihypertensive medications had a lower risk of being admitted to the hospital for a mood disorder than those who did not.

In the Media

Penn Live Mental health care: How to spot the warning signs of severe mental illness January 24, 2013
Medical Xpress Stressed out? Tips for taking control January 14, 2013
Chosunilbo Long Working Hours Linked to Depression January 27, 2012
CNN Health Working long hours doubles depression odds January 26, 2012
Reuters Exercise may boost mood for some chronically ill January 25, 2012